Long-term safety of α-lipoic acid (ALA) consumption: A 2-year study

Cremer, D.; Rabeler, R.; Roberts, Ashley; Lynch, Barry

doi:10.1016/j.yrtph.2006.06.003

Cited by 91 publications

(60 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the early 1990s, ·-lipoic acid has been used as a dietary supplement for humans, typically at doses in the range of 60-200 mg/day. In addition, the no observable adverse effect level (NOAEL) is considered to be 60 mg/kg wt/day (35). However, despite growing evidence of the benefits of ET or LA for the health and function of AD patients, there is little clinical evidence that supports the recommendations for ·-lipoic acid supplementation and ET guidelines in AD patients.…”

Section: Discussionmentioning

confidence: 99%

The combination of exercise training and α-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice

Cho¹

2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Exercise training was suggested as a practical therapeutic strategy for human subjects suffering from Alzheimer's disease (AD) in our previous study. Therefore, the purpose of this study was to investigate the effects of combining exercise training with the administration of antioxidants on the pathological phenotype of AD. To accomplish this, non-transgenic mice (Non-Tg) and NSE/ APPsw Tg mice were treated with ·-lipoic acid and treadmill exercised for 16 weeks, after which their brains were evaluated to determine whether any changes in the pathological phenotype-related factors occurred. The results indicated that (i) the combination-applied (COMA) Tg group with exercise training (ET) and ·-lipoic acid administration (LA) showed ameliorated spatial learning and memory compared to the sedentary (SED)-Tg and single-treatment groups; (ii) there were no differences in the level of Aß-42 peptides across groups; (iii) the level of glucose transporter-1 and brain-derived neurotrophic factor proteins were highly increased in the COMA group, (iv) ET and LA did not induce a synergistic effect on the expression of heat shock protein-70 and apoptotic proteins including Bax and caspase-3; (v) the levels of SOD-1 and CAT suppressing oxidative stress were extensively higher in the COMA than in the singletreated groups and (vi) there were no significant differences across groups regarding these serum characteristics, although these levels were lower than the SED-Tg group. Taken together, these results suggest that the combination with ET and LA may contribute to protect the neuron injury induced by Aß peptides and may be considered an effective therapeutic strategy for human subjects suffering from AD.

show abstract

Section: Discussionmentioning

confidence: 99%

The combination of exercise training and α-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice

Cho¹

2010

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Прегабалін -модулятор ноцицептивної та антиноцицептивної систем центральної дії з доведеною ефективністю щодо невропатичного болю, але з седативним ефектом (15%-25%), який обмежує титрацію дози. В дослідженнях, що вивчали дози α-ЛК 1200 мг на добу та більше, повідомлялося про такі побічні ефекти як нудота та блювання [39]. Проте в дослідженні безпеки в дозах 900 мг/день протягом 6 тижнів, а потім 1200 мг на день ще 6 тижнів, у поєднанні з пероральними цукрознижувальними засобами (метформіном, похідними сульфонілсечовини, глітазонами) та інсулінотерапією у хворих на ЦД 2 типу не спостерігалося серйозних побічних явищ чи відхилень біохімічних показників крові [40].…”

Section: патофізіологічні передумови та ефекти α-лкunclassified

Alpha-lipoic acid in treatment of diabetes mellitus complications

Юзвенко¹,

Krushinska²,

Тарасенко³

2017

CE&ES

View full text Add to dashboard Cite

“…Both in vitro and in vivo studies revealed that a new α-LA (DHL-HisZn, sodium zinc histidine dithiooctanamide) reduced serum levels of BUN and SCr, decreased MDA levels and ROS levels as well as alleviated the severity of kidney lesions (tubular cell necrosis, cytoplasmic vacuolation, hemorrhage and tubular dilatation) [27]. No acute, subacute and long-term toxicity by α-LA were found in both in vitro and in vivo studies [28,29]. LA was also shown to protect cisplatin-induced nephrotoxicity via oxidant defense system [29,34].…”

Section: Mechanisms Of La Cardioprotectionmentioning

confidence: 99%

“…In this context, LA has been shown to improve glucose and ascorbate handling, increase endothelial nitric oxide synthase activity, activate phase II detoxification via the transcription factor Nrf2 and lower expression of matrix metalloproteinase-9 and vascular cell adhesion molecule-1 through repression of nuclear factor-κB (NF-κB) [17]. In addition, animal studies have revealed that myocardial IRI [18,19,20,21,22,23] and renal IRI [24,25,26,27] could be protected by a naturally occurring cellular antioxidant LA, without being toxic to rats [28,29]. The mechanisms whereby LA exerts its protective effects are not entirely understood, but may be related to the phosphatidylinositol 3-kinase (PI3K)/Akt/Nrf2 pathway [23] and the PI3-kinase/Akt pathway, as ischemic preconditioning (IPC) reduces IRI of the rat liver via these pathways [30].…”

Section: Introductionmentioning

confidence: 99%

Lipoic Acid in the Prevention of Acute Kidney Injury

Zhang

McCullough²

2016

Nephron

View full text Add to dashboard Cite

Hypoxia, reactive oxygen species (ROS) and oxidative stress contribute to contrast-induced acute kidney injury (CI-AKI) and ischemic reperfusion injury (IRI) in the kidney and heart. Imbalance between the increased formation of ROS by hypoxia in the cardiac and renal tissue and the low availability of endogenous antioxidants is a common cause of cellular and tissue damage. Therefore, a strategy to inhibit ROS generation or to scavenger free radicals becomes an important intervention to prevent CI-AKI and myocardial IRI. Evidence has shown that a naturally occurring cellular antioxidant lipoic acid (LA) (1,2-dithilane-3-pentanoic acid) acts as a free radical scavenger of ROS and reactive nitrogen oxide species for cardioprotection and renoprotection. The mechanisms whereby LA exerts its protective effects are not entirely understood, but may be related to the phosphatidylinositol 3-kinase/Akt/Nrf2 pathway and the PI3-kinase/Akt pathways. This review will provide the current information of LA as an exogenous antioxidant for cardioprotection and renoprotection, with emphasis on antioxidant functions of LA and multiple signaling pathways underlying protective effects of LA on CI-AKI as well as cardiac and renal IRI.

show abstract

Long-term safety of α-lipoic acid (ALA) consumption: A 2-year study

Cited by 91 publications

References 29 publications

The combination of exercise training and α-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice

The combination of exercise training and α-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice

Alpha-lipoic acid in treatment of diabetes mellitus complications

Lipoic Acid in the Prevention of Acute Kidney Injury

Contact Info

Product

Resources

About